TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Nxera Pharma
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

Nxera Pharma reported progress in its obesity and metabolic disease pipeline, achieved R&D milestones with AbbVie, and advanced cancer immunotherapy trials. The company experienced increased R&D expenses and a wider operating loss compared to the previous period.

Insights
ABBV   positive

Successfully reached second R&D milestone in multi-target discovery collaboration, receiving a $10 million payment from Nxera